Diabetes in pregnancy.

Area of Science:

• Obstetrics and Gynecology
• Endocrinology
• Public Health

Background:

• Diabetes in pregnancy remains a high-risk condition, associated with significantly increased malformation and mortality rates.
• Rising global rates of type 2 diabetes in pregnancy, coupled with maternal obesity, exacerbate management challenges and adverse outcomes.
• Despite evidence linking even mild hyperglycemia to poor pregnancy outcomes (HAPO study), clinical practice translation remains difficult.

Purpose of the Study:

• To review recent advancements in managing diabetes during pregnancy.
• To assess the evolving role of pharmacological interventions and technological aids in pregnancy diabetes care.
• To highlight the long-term health implications of gestational hyperglycemia for mother and child.

Main Methods:

• Review of randomized controlled trials and emerging technologies over the past 5-10 years.
• Analysis of data regarding oral hypoglycemic agents, insulin analogs, continuous subcutaneous insulin infusion (CSII) pumps, and continuous glucose monitors (CGMs).
• Consideration of findings from landmark studies like the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study.

Main Results:

• Recent trials provide new insights into the use of oral hypoglycemic drugs and insulin analogs in pregnancy.
• Continuous glucose monitoring and insulin pump technologies are under active investigation for their utility.
• The HAPO study confirmed the association between hyperglycemia, even at minor degrees, and adverse pregnancy outcomes.

Conclusions:

• Effective management of diabetes in pregnancy is crucial due to persistent high-risk factors and increasing prevalence.
• Technological advancements offer potential for improved glycemic control and outcomes.
• Recognizing the long-term metabolic and cardiovascular consequences of gestational hyperglycemia is essential for public health strategies.